Sorafenib (Nexavar)

Sorafenib, sold under the brand name Nexavar, is an oral targeted therapy known as a multi-kinase inhibitor. It works by blocking several proteins that cancer cells use to grow and to build new blood vessels. It is FDA-approved for advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), and certain thyroid cancers, and has been studied off-label in mesothelioma.

Origin

Sorafenib was developed by Bayer and Onyx Pharmaceuticals and received FDA approval in 2005 for advanced renal cell carcinoma. The "-fenib" suffix follows the World Health Organization naming convention for small-molecule kinase inhibitors, and the brand name Nexavar combines references to its novel mechanism and antiviral/antitumor action on vascular signaling.

Significance in Asbestos Context

For patients with asbestos-related cancers, sorafenib is most relevant if you have been diagnosed with kidney cancer, which some studies have associated with asbestos exposure. It has also been tested in clinical trials for pleural mesothelioma, though results have been modest and it is not a standard first-line treatment for that disease. If your oncologist proposes sorafenib, ask whether it is being used on-label for your specific cancer or as part of a clinical trial, and make sure the treatment, response, and side effects are well documented in your medical records. This information can be important if your case involves claims for medical expenses, pain and suffering, or reduced life expectancy.

Example Sentence

After his renal cell carcinoma progressed despite surgery, the oncologist started him on sorafenib (Nexavar) and added the prescription records to the file his attorney was building for his asbestos claim.

Related Terms

Targeted Therapy, Tyrosine Kinase Inhibitor, Renal Cell Carcinoma, Hepatocellular Carcinoma, Angiogenesis Inhibitor, Mesothelioma

Notes

• Ask your oncologist whether sorafenib is the best fit for your cancer type and stage, or whether newer immunotherapy or combination regimens (such as checkpoint inhibitors) may now be preferred.
• Common side effects include hand-foot skin reaction, high blood pressure, diarrhea, fatigue, and hair changes; report these promptly because dose adjustments can usually keep you on therapy.
• Keep copies of all prescriptions, infusion or pharmacy records, and bills for sorafenib. It is an expensive drug (often tens of thousands of dollars per year), and these costs are recoverable as economic damages in an asbestos claim.
• If sorafenib is being offered through a clinical trial for mesothelioma or another asbestos-linked cancer, ask for the trial protocol and informed consent documents, and keep copies for your records.